EUCTR2009-012456-25-DE进行中（未招募）不适用
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIMEBON (LATREPIRDINE, PF-01913539) IN PATIENTS WITH MODERATE-TO-SEVERE ALZHEIMER’S DISEASE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 576
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Are men and women =50 years of age with a diagnosis of probable AD according to the following criteria:
- •a. Diagnostic and Statistical Manual of Mental Disorders IV Text Revision (DSM IV TR)as listed in Appendix 1 of the protocol
- •b. National Institute of Neurological and Communicative Disorders and Stroke -Alzheimer’s Disease and Related Disorder Association’s Criteria (NINCDS ADRDA) for probable AD
- •c. MMSE score between 5 and 14 inclusive
- •d. Modified Hachinski Ischemic Score =4
- •2. Are willing and able to give informed consent. If the patient is deemed to not have capacity to provide consent, a mentally competent legally acceptable representative must provide informed consent on their behalf, and the patient must provide assent
- •3. Have had brain imaging such as magnetic resonance imaging (MRI) and/or computed tomography (CT) approximately within twelve months of Screening, consistent with a diagnosis of probable AD without any other clinically significant co morbid pathologies found. If there has been a significant change in clinical status suggestive of stroke or other possible central neurological disease with onset between the time of the last MRI or CT and the Screening evaluation, the scan should be repeated if considered appropriate by the Investigator
- •4. Must be on background anti-demtia monotherapy only with the NMDA receptor antagonist, memantine, for a minimum of six (6) months preceding the Screening MMSE and at a stable dose and regimen orally daily for at least four (4) months with no intent to change this regimen while participating in the study
- •5. Must be or have previously (in pre AD condition) been literate, and capable of reading, writing, and communicating effectively with others
- •6. Have a caregiver who assists the patient at least five days per week for at least three hours per day and has intimate knowledge of the patient’s cognitive, functional, and emotional states, and of the patient’s personal care. The caregiver must be willing to accompany the patient to all study visits and to supervise study drug administration, as well as report adverse events. The caregiver must be willing and able to give informed consent for their own participation, be able to read and write, and be capable of providing responses to the CIBIC plus, ADCS ADLsev, NPI, EQ 5D, and RUD Lite assessment tools
- •7. If female, is either a) of reproductive potential and compliant in using adequate birth control or b) not of reproductive potential. Adequate birth control is defined as consistent practice of an effective and accepted method of contraception (hormone based, intrauterine device, or double barrier contraception, ie, condom and diaphragm, diaphragm and spermicidal gel or foam) throughout the duration of the study. Abstinence is an acceptable method of contraception. Female patients not of reproductive potential may be patients who have undergone menopause, hysterectomy, bilateral oophorectomy, or bilateral tubal ligation. Menopause is defined as 1 year without menses. If the patient’s menopausal status is in question, a follicle stimulating hormone (FSH) level of >40 milli international units per milliliter (mIU/mL) must be documented. Hysterectomy, bilateral oophorectomy, or bilateral tubal ligation must be documented; and
- •8. If male, is either a) of reproductive potential and compliant in using adequate birth control or are b) not of reproductive potential. Surgical sterilization must be documented. Adequate birth control
排除标准
- •1. Have clinically important structural brain disease (eg, ischemic infarcts, subdural
- •hematoma, hemorrhage, etc.);
- •2. Have any major medical illness or unstable medical condition within six months of
- •Screening that, in the opinion of the investigator, may interfere with the patient’s ability to comply with study procedures and abide by study restrictions, or with the ability to interpret safety data, including:
- •a. Any physical disability that would prevent completion of study procedures or
- •assessments
- •b. A history of cancer within five years of enrollment with the exception of
- •non-melanoma skin cancers or prostate cancer that has been stable for at least six
- •months or Grade 0 or Grade 1 cancers that have a remote probability of recurrence,;
- •c. The following cardiovascular parameters:
- •Hypotension - systolic blood pressure <86 millimeters of mercury (mmHg) or
- •bradycardia with heart rate less than 50 beats per minute;
- •Uncontrolled hypertension as indicated by a resting systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg;
- •A corrected QT interval by the Fridericia correction formula (QTcF) of greater than 470 milliseconds (msec) on an electrocardiogram (ECG) at the Screening Visit based on value from central over-read;
- •Active cardiovascular disease..
- •d. A history of traumatic brain injury with remaining neurological deficit;
- •e. A diagnosis of a dementing central nervous system disease other than AD;
- •f. A history of epilepsy or seizure disorder requiring ongoing treatment, or any seizure or unexplained loss of consciousness within the six months preceding Screening;
- •g. Any current psychiatric diagnosis according to DSM-IV-TR that may interfere with
- •the patient’s ability to perform the study and all assessments;.
- •3. Are pregnant or lactating females;
- •4. Reside in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision;
- •5. Have a caregiver who is paid to care for more than two patients, unless that caregiver is clinically trained;
- •6. Have a history of previous exposure to dimebon or who have participated in a previous dimebon clinical trial;
- •7. Have known human immunodeficiency virus (HIV) seropositivity.;
- •8. Have any of the following laboratory abnormalities at the Screening visit:
- •a. Clinically significant Vitamin B12 levels less than the lower limit of normal (LLN) or
- •on replacement Vitamin B12 for less than three months prior to enrollment;
- •b. Clinically significant folate levels less than the lower limit of normal or on
- •replacement folate therapy for less than three months prior to enrollment;
- •c. Thyroid-stimulating hormone (TSH) levels greater than the upper limit of normal
- •(ULN) AND a free thyroxine lower than the lower limit of normal;
- •d. Positive Rapid Plasma Reagin (RPR) confirmed by Fluorescent Treponemal
- •Antibody - Absorption [FTA-ABS]);
- •e. Total bilirubin (Tbili), alanine aminotransferase (ALT), or aspartate aminotransferase (AST) levels greater than two times the upper limit of normal;
- •f. Renal impairment with a serum creatinine (Cr) >133 µmol/L (1.5 mg/dL);
- •g. Hematocrit, absolute neutrophil count, and/or platelet count below the LLN indicating clinically significant anemia, neutropenia, and/or thrombocytopenia.
- •9. Taken or plan to take prescribed anti-dementia agents besides memantine, from 2 months prior to the screening MMSE through the End of Study;
- •10. Have taken a prescription medical food or prescription nutriceuticals marketed for AD;
研究者
相似试验
进行中（未招募）
不适用
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF THE LONG-TERM ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ALONE OR IN COMBINATION WITH NON-STEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS) VERSUS NSAIDS ALONE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIPEUCTR2008-004815-37-NLPfizer Inc., 235 East 42nd Street, New York, NY 100172,500
进行中（未招募）
1 期
A randomized, double-blind double-dummy Phase 3 study performed at multiple study sites to evaluate the safety, efficacy and tolerability of the combinational product Carbavance (Meropenem/RPX7009) in comparison to Piperacillin/Tazobactam which is already approved in many countries to treat patients with complicated urinary tract infections, including acute pyelonephritis, in adults.EUCTR2014-000545-78-CZRempex Pharmaceuticals, Inc.500
进行中（未招募）
1 期
A randomized, double-blind double-dummy Phase 3 study performed at multiple study sites to evaluate the safety, efficacy and tolerability of the combinational product Carbavance (Meropenem/RPX7009) in comparison to Piperacillin/Tazobactam which is already approved in many countries to treat patients with complicated urinary tract infections, including acute pyelonephritis, in adults.complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) with or without concurrent bacteremiaMedDRA version: 18.1Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-000545-78-BGRempex Pharmaceuticals, Inc.500
进行中（未招募）
不适用
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION WHO HAVE COMPLETED STUDY B1321001Pulmonary Arterial HypertensionMedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-005887-14-CZPfizer Ltd.150
进行中（未招募）
1 期
A randomized, double-blind double-dummy Phase 3 study performed at multiple study sites to evaluate the safety, efficacy and tolerability of the combinational product Carbavance (Meropenem/RPX7009) in comparison to Piperacillin/Tazobactam which is already approved in many countries to treat patients with complicated urinary tract infections, including acute pyelonephritis, in adults.complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) with or without concurrent bacteremiaMedDRA version: 19.0Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-000545-78-PLRempex Pharmaceuticals, Inc.500